Comparison of the Diagnostic Accuracy: US-guided Percutaneous Lung Biopsies vs CT-guided in Peripheral Lung Lesions

Launched by UNIVERSITY HOSPITAL OF FERRARA · May 8, 2024

Keywords

ClinConnect Summary

This clinical trial is exploring two different methods of taking samples from lung lesions that are near the outer part of the lung, called peripheral lung lesions. The study is comparing ultrasound-guided lung biopsies, where sound waves help guide the needle, to CT-guided biopsies, which use detailed X-ray images. The goal is to find out which method is more accurate in diagnosing issues with these lung lesions. Additionally, the trial will look at factors like how comfortable patients feel during the procedure, the time it takes to complete it, and any complications that might arise.

To participate in this study, individuals must be at least 18 years old and be willing to give their consent. They should have lung lesions that are close to the chest wall, as seen on a CT scan, and require diagnosis. However, some people may not be eligible, such as those with severe health issues, those who cannot give consent, or pregnant women. Participants can expect to undergo either type of biopsy and will be monitored for any side effects or complications during and after the procedure. This study could help improve the way lung lesions are diagnosed in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Willingness and ability to provide free and informed consent. Age older then 18 years old.
• • Peripheric pulmonary lesions adherent to the thoracic wall in CT scans with indication to typing
• Exclusion Criteria:
• • Inability to provide free and informed consent, in the absence of an available legal guardian.
• • Age younger then 18 years old.
• • Terminal neoplastic diseases/ palliative care patients.
• • Patients with one lung, anatomical of functional.
• • Severe non-treatable blood clothing disfunctions.
• • Severe organ failure (pulmonary, renal, hepatic or cardiac).
• • Women in state of pregnancy.